These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25890698)

  • 1. Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.
    Marshall AJ; Lill CL; Chao M; Kolekar SV; Lee WJ; Marshall ES; Baguley BC; Shepherd PR; Denny WA; Flanagan JU; Rewcastle GW
    Bioorg Med Chem; 2015 Jul; 23(13):3796-808. PubMed ID: 25890698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
    Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors.
    Lin H; Erhard K; Hardwicke MA; Luengo JI; Mack JF; McSurdy-Freed J; Plant R; Raha K; Rominger CM; Sanchez RM; Schaber MD; Schulz MJ; Spengler MD; Tedesco R; Xie R; Zeng JJ; Rivero RA
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2230-4. PubMed ID: 22361133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
    Stamatkin C; Ratermann KL; Overley CW; Black EP
    Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
    Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors.
    Kendall JD; Rewcastle GW; Frederick R; Mawson C; Denny WA; Marshall ES; Baguley BC; Chaussade C; Jackson SP; Shepherd PR
    Bioorg Med Chem; 2007 Dec; 15(24):7677-87. PubMed ID: 17869522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.
    Giordanetto F; Wållberg A; Ghosal S; Iliefski T; Cassel J; Yuan ZQ; von Wachenfeldt H; Andersen SM; Inghardt T; Tunek A; Nylander S
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6671-6. PubMed ID: 23010262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
    Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
    Certal V; Carry JC; Halley F; Virone-Oddos A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Karlsson A; Charrier V; Delorme C; Rak A; Abecassis PY; Amara C; Vincent L; Bonnevaux H; Nicolas JP; Mathieu M; Bertrand T; Marquette JP; Michot N; Benard T; Perrin MA; Lemaitre O; Guerif S; Perron S; Monget S; Gruss-Leleu F; Doerflinger G; Guizani H; Brollo M; Delbarre L; Bertin L; Richepin P; Loyau V; Garcia-Echeverria C; Lengauer C; Schio L
    J Med Chem; 2014 Feb; 57(3):903-20. PubMed ID: 24387221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport.
    Li J; Song J; Cassidy MG; Rychahou P; Starr ME; Liu J; Li X; Epperly G; Weiss HL; Townsend CM; Gao T; Evers BM
    Mol Endocrinol; 2012 Aug; 26(8):1380-93. PubMed ID: 22700584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?
    Singh P; Dar MS; Dar MJ
    FEBS Lett; 2016 Sep; 590(18):3071-82. PubMed ID: 27552098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
    Finlay MR; Buttar D; Critchlow SE; Dishington AP; Fillery SM; Fisher E; Glossop SC; Graham MA; Johnson T; Lamont GM; Mutton S; Perkins P; Pike KG; Slater AM
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4163-8. PubMed ID: 22607682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
    Rewcastle GW; Gamage SA; Flanagan JU; Frederick R; Denny WA; Baguley BC; Kestell P; Singh R; Kendall JD; Marshall ES; Lill CL; Lee WJ; Kolekar S; Buchanan CM; Jamieson SM; Shepherd PR
    J Med Chem; 2011 Oct; 54(20):7105-26. PubMed ID: 21882832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements.
    Large JM; Torr JE; Raynaud FI; Clarke PA; Hayes A; Stefano Fd; Urban F; Shuttleworth SJ; Saghir N; Sheldrake P; Workman P; McDonald E
    Bioorg Med Chem; 2011 Jan; 19(2):836-51. PubMed ID: 21216151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PI3K p110β in the differentiation of human embryonic stem cells into islet-like cells.
    Mao GH; Lu P; Wang YN; Tian CG; Huang XH; Feng ZG; Zhang JL; Chang HY
    Biochem Biophys Res Commun; 2017 Jun; 488(1):109-115. PubMed ID: 28479244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antitumor activity of novel pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one derivatives.
    El-Nassan HB
    Eur J Med Chem; 2011 Jun; 46(6):2031-6. PubMed ID: 21429629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinase isoform-specific effects in airway mesenchymal cell function.
    Moir LM; Trian T; Ge Q; Shepherd PR; Burgess JK; Oliver BG; Black JL
    J Pharmacol Exp Ther; 2011 May; 337(2):557-66. PubMed ID: 21349933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhibitors.
    Schwehm C; Kellam B; Garces AE; Hill SJ; Kindon ND; Bradshaw TD; Li J; Macdonald SJ; Rowedder JE; Stoddart LA; Stocks MJ
    J Med Chem; 2017 Feb; 60(4):1534-1554. PubMed ID: 28128944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 4H-benzo[e][1,3]oxazin-4-ones analogues of TGX-221 as inhibitors of PI3Kβ.
    Mohammed EUR; Porter ZJ; Jennings IG; Al-Rawi JMA; Thompson PE; Angove MJ
    Bioorg Med Chem; 2022 Sep; 69():116832. PubMed ID: 35752141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.